SCHEMBL395986

SCHEMBL395986

Cc1cc(O)c(C(C)(C)C)c(C)c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.41
ALOX15 P16050 6/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
TP53 P04637 3/20 0.41
TDP1 Q9NUW8 3/20 0.41
CYP3A4 P08684 2/20 0.41
MAPK1 P28482 2/20 0.41
HIF1A Q16665 2/20 0.41
TSHR P16473 1/20 0.41
MAPT P10636 4/20 0.39
CYP1A2 P05177 3/20 0.39
KDM4E B2RXH2 3/20 0.39
ATP2A2 P16615 1/20 0.39
ATP2A3 Q93084 1/20 0.39
CYP2C9 P11712 4/20 0.37
CYP2C19 P33261 3/20 0.37
HSD17B10 Q99714 3/20 0.37
CYP2D6 P10635 2/20 0.37
HPGD P15428 2/20 0.37
G6PD P11413 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8657395 0.86 ALDH1A1 (0.41) ALDH1A1ALOX15SMN1; SMN2TP53TDP1
SCHEMBL784959 0.84 CYP2C9 (0.43) ALDH1A1ALOX15SMN1; SMN2TP53TDP1
SCHEMBL12149768 0.83 ACHE (0.42) ALDH1A1ALOX15SMN1; SMN2TP53TDP1
SCHEMBL9844420 0.81 ALDH1A1 (0.41) ALDH1A1ALOX15SMN1; SMN2TP53TDP1
SCHEMBL9339204 0.81 ALDH1A1 (0.41) ALDH1A1ALOX15SMN1; SMN2TP53TDP1
SCHEMBL785259 0.80 POLB (0.45) ALDH1A1ALOX15SMN1; SMN2TP53TDP1
SCHEMBL2244012 0.79 ALOX15 (0.54) ALDH1A1ALOX15SMN1; SMN2TP53TDP1
SCHEMBL784926 0.77 ALDH1A1 (0.35) ALDH1A1ALOX15SMN1; SMN2TP53TDP1
SCHEMBL785191 0.74 CYP2C9 (0.43) ALDH1A1ALOX15SMN1; SMN2TP53TDP1
SCHEMBL28613619 0.74 ALOX15 (0.54) ALDH1A1ALOX15SMN1; SMN2TP53TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112724302-B Ethylene-alpha-olefin copolymer, process for producing the same, ethylene resin composition, and film 住友化学株式会社 2023-10-31 CN disclosed
US-11643533-B2 Film, method of producing film, and bag SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-05-09 US disclosed
CN-110352213-B Film 住友化学株式会社 2022-09-09 CN disclosed
US-11149102-B2 Film SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-10-19 US disclosed
US-20210284829-A1 FILM, METHOD OF PRODUCING FILM, AND BAG SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-09-16 US disclosed
EP-3878896-A1 FILM, METHOD OF PRODUCING FILM, AND BAG SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2021-09-15 EP disclosed
CN-113387055-A Film, method for producing film, and bag 住友化学株式会社 2021-09-14 CN disclosed
EP-3816198-A1 ETHYLENE-ALPHA-OLEFIN COPOLYMER, METHOD OF PRODUCING ETHYLENE-ALPHA-OLEFIN COPOLYMER, ETHYLENE-BASED RESIN COMPOSITION, AND FILM SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2021-05-05 EP disclosed
CN-112724302-A Ethylene-alpha-olefin copolymer, process for producing the same, ethylene resin composition, and film 住友化学株式会社 2021-04-30 CN disclosed
US-20210122854-A1 ETHYLENE-alpha-OLEFIN COPOLYMER, METHOD OF PRODUCING ETHYLENE-alpha-OLEFIN COPOLYMER, ETHYLENE-BASED RESIN COMPOSITION, AND FILM SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-04-29 US disclosed
US-20030069127-A1 Modified particle,support, catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMTED (JP) 2003-04-10 US disclosed
EP-1300425-A2 Catalyst component for addition polymerization, process for producing said catalyst and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-04-09 EP disclosed
US-20030060579-A1 Catalyst component for addition polymerization, process for producing catalyst for addition polymerization and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-03-27 US disclosed
EP-1275662-A1 MODIFIED PARTICLE, SUPPORT, CATALYST COMPONENT FOR ADDITION POLYMERIZATION, CATALYST FOR ADDITION POLYMERIZATION, AND PROCESS FOR PRODUCING ADDITION POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-01-15 EP disclosed
US-20020143124-A1 Homogeneous type solid catalyst component or homogeneous type solid catalyst, process for production thereof and process for producing addition polymer with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-10-03 US disclosed
US-20020013433-A1 Transition metal compound, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-01-31 US disclosed
US-20010053832-A1 Olefin polymerization catalyst and process for producing olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-12-20 US disclosed
EP-1153938-A1 CATALYST FOR STEREOREGULAR POLYMERIZATION OF ALPHA-OLEFIN AND PROCESS FOR PRODUCING STEREOREGULAR ALPHA-OLEFIN POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-11-14 EP disclosed
EP-1134234-A1 Olefin polymerization catalyst and process for producing olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-09-19 EP disclosed
EP-1081167-A1 Olefin polymerization catalyst and process for producing olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013433-A1 Transition metal compound, catalyst for addition polymerization, and process for producing addition polymer ASH2L, ARL1, AS3MT ALDH1A1 3244/4885ALOX15 1683/4885SMN1; SMN2 3287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.